RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Exemestane encapsulated copolymers L121/F127/GL44 based mixed micelles: solubility enhancement and in vitro cytotoxicity evaluation using MCF-7 breast cancer cells

        Singh Gurdeep,Singh Davinder,Choudhari Manisha,Kaur Simran Deep,Dubey Sunil Kumar,Arora Saroj,Bedi Neena 한국약제학회 2021 Journal of Pharmaceutical Investigation Vol.51 No.6

        Purpose The present study aimed to develop a novel therapeutic approach for controlled delivery of exemestane (EXE) to cancer cells using nanostructured polymeric micelles. Methods A simplex centroid design of experiment study was employed for optimizing the polymeric micelle formulation to achieve the desired critical quality attributes, including micelle size, drug loading (DL), encapsulation efficiency (EE), and critical micelle concentration (CMC). The oil-in-water (o/w) solvent evaporation method was used to prepare mixed micelles (MMs) of copolymers L121/F127/GL44 for encapsulating EXE. Profile analysis tensiometer methods were used to determine the CMC of the copolymer mixture. EXE-MMs, blank mixed micelles, and lyophilized mixed micelles (Lyp- EXE-MMs) were characterized for other key quality attributes, such as zeta potential, chemical interactions, and morphology. Results The optimized ratio of L121/F127/GL44 was 1.98, 0.812, and 1.20, respectively, providing EXE-MMs with small micelle sizes (35.45 ± 1.20 nm), higher EE (89.75 ± 2.14%), and DL (5.85 ± 2.14%). EXE-encapsulated MMs exhibited an in vitro sustained release profile with improved cytotoxicity against MCF-7 cells than that with pure EXE. The cellular growth inhibitory concentration ( IC50) of EXE-MMs was 0.225 ± 0.124 μg/ml, while that of naïve EXE was 7.58 ± 0.145 μg/ ml. Moreover, in vivo pharmacokinetic parameters of EXE micellar formulation showed significant improvement in Cmax and AUC (0–72 h), viz. 207.54 ± 18.65 ng/ml and 3530.77 ± 212.25 ng h/ml, respectively, suggesting enhanced bioavailability than that of pure EXE. Conclusion EXE-MMs have a great potential for enhancing the bioavailability of EXE.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼